This research uses a validated rodent model of psychosis to study sensory-filtering deficits linked to schizophrenia. Instead of blocking dopamine D2 receptors, the study uses CDPPB to modulate mGlu5 receptors and reduce D2 hypersensitivity. Treatment restores normal sensory gating, suggesting a promising therapeutic pathway with fewer side effects than current antipsychotics.

This research investigates transcranial electrical stimulation (tACS) as a non-invasive way to modulate prefrontal cortex activity in people with severe mental disorders such as schizophrenia. By measuring brain activity, cognition, and behavior, the study aims to identify conditions where tACS is effective and offer a safe, accessible therapeutic alternative.